Han Yu Pharmaceutical: Signed a cooperation framework agreement with the partner for the sale of peptide raw materials, with a sales amount not less than 327 million yuan.

Han Yu Pharmaceuticals announced that the company signed a framework agreement for the sales of polypeptide raw materials with a partner on May 18, 2026, with a planned sales amount of not less than 327 million yuan, accounting for 33.84% of the company's most recent audited operating income. The purpose of this cooperation is to expand overseas business layout and accelerate the commercialization process of GLP-1 raw materials. The implementation of the agreement will have a positive impact on the company's future financial condition and operating results.